Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | NMBR | P28336 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880965 | 0.88 | TACR1 (0.60) | TACR1MAPTLMNABAZ2BNMBR | |
| SCHEMBL5881165 | 0.81 | TACR1 (0.52) | TACR1NMBRKDM4EALDH1A1HPGD | |
| SCHEMBL6609382 | 0.79 | TACR1 (0.51) | TACR1MAPTLMNABAZ2BNMBR | |
| SCHEMBL5880946 | 0.78 | TACR1 (0.45) | TACR1MAPTNMBRKDM4EALDH1A1 | |
| SCHEMBL14003981 | 0.78 | TACR1 (0.52) | TACR1MAPTLMNABAZ2BNMBR | |
| SCHEMBL5881032 | 0.76 | TACR1 (0.51) | TACR1MAPTLMNABAZ2BNMBR | |
| SCHEMBL5881130 | 0.73 | TACR1 (0.47) | TACR1MAPTLMNANMBRKDM4E | |
| SCHEMBL17999310 | 0.73 | TACR1 (0.43) | TACR1LMNABAZ2BNMBR | |
| SCHEMBL17999311 | 0.73 | TACR1 (0.43) | TACR1LMNABAZ2BNMBR | |
| SCHEMBL9476489 | 0.72 | KDM4E (0.50) | MAPTLMNABAZ2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | claimed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | claimed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | claimed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | TACR1 300/4885MAPT 2593/4885LMNA 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.